李泽钜提到，目前公司正在开展多个癌症疫苗研发项目，其中包括上个月公布的TROP2癌症疫苗项 目。TROP2是一种在多类癌症中有过度表现的蛋白，常见于三阴性乳癌、肺癌、胃癌、结直肠癌、胰 脏癌、前列腺癌及卵巢癌。公司的TROP2融合蛋白和circRNA癌症疫苗在4项临床前研究中被发现能大 幅度抑制肿瘤生长，于乳癌和结直肠癌小鼠模型中显示 100%的肿瘤生长抑制。估计大约需要24-30个月 的时间便能开始I/II期临床试验。 智通财经APP获悉，长江生命科技(00775)主席李泽钜近日在股东周年大会中表示，生物科技研究是属于 一个高回报、高风险的行业。如果研究成功的话，只需一只产品，它的价值有机会可以高过很多上市基 建甚至地产公司。如果买股票纯粹为收息，可能买基建或收租股较适合。其认为，如果公司有一个全面 性投资组合，将一部分资金投放于这类高值博率投资上是正确的。 至于是否分拆其生物制药部门在香港上市，李泽钜表示，公司会不断评估策略机遇，以提高股东价值并 优化公司业务结构。目前，公司没有任何需要发布的公告，并将随时向市场通报任何重大进展。针对是 否有意通过配股或者可转换债券集资以帮助研发，他回应称，公司尚未发布任 ...

Group 1 - Jiangsu Life Science Technology (00775.HK) recently announced promising early results from preclinical laboratory tests of its novel cancer vaccine targeting trophoblast cell surface antigen 2 (TROP2) [1] - The TROP2 vaccine has shown significant tumor growth inhibition in preclinical studies, with four out of five studies demonstrating 100% tumor growth suppression and one study showing approximately 80% suppression in over 170 mice [1] - The TROP2 vaccine is expected to become the first curative therapy for high-incidence cancers in Asia, addressing urgent clinical needs and potentially covering multiple cancer types such as lung and pancreatic cancer [1] Group 2 - The company has multiple clinical-stage medical research projects and its R&D product line is considered severely undervalued, with potential for value release and substantial performance contributions [2] - The company reported a nearly 60% year-on-year increase in clinical trial and laboratory expenses, reaching HKD 161 million in 2024, indicating a strong commitment to R&D [2] - The company is exploring various strategic options, including strategic partnerships, joint ventures, business spin-offs, and mergers, to maximize shareholder value and enhance its capital acquisition channels [2]

美团-W(03690)早盘涨3.82%，机构预计外卖行业竞争格局将保持稳定，平台价值有望长期释放。 智通财经APP获悉，港股恒生指数涨0.12%，涨26点，报21998点；恒生科技指数涨0.81%；港股早盘成 交973亿港元。 蚂蚁拟斥资28.14亿港元收购耀才证券控股权，阿里系板块全线走高。耀才证券金融(01428)再涨20%； 阿里健康（00241）涨6%。 上美股份(02145)涨8%，股价续刷历史新高，机构看好美护板块优质标的长期成长性。 泰格医药(03347)绩后跌超2%，一季度归母净利同比减少近三成，机构指其毛利率水平仍有提升空间。 青岛啤酒股份(00168)绩后跌3.7%，一季度净利润同比增长7.08%。 长江生命科技(00775)再涨超9%，公司在AACR 2025展示多种癌症疫苗数据。 龙源电力(00916)绩后跌超6%，一季度归母净利同比减少21.82%，风电分部收入同比减少1.89%。 荣昌生物(09995)绩后跌8.21%，一季度营收同比增近六成，亏损收窄至2.54亿元。 地平线机器人-W(09660)涨超9%，近日与电装达成战略合作，机构指产业链景气度确定性上行。 赤子城科技(099 ...

Core Insights - The company, Changjiang Life Sciences (00775), will present the latest preclinical research data on its cancer vaccine at the AACR 2025 Annual Meeting in Chicago [1][2] - The cancer vaccine targets several proteins, including Preferentially Expressed Antigen in Melanoma (PRAME), programmed cell death-ligand 1 (PD-L1), B7 homolog 3 (B7-H3), and Claudin 6 [1][2] - The company is satisfied with the preclinical efficacy results of the cancer vaccines targeting these proteins and aims to advance them to clinical stages [2] Research and Development - PRAME is a protein highly expressed in melanoma, liver cancer, and blood cancers [1] - PD-L1 is a crucial immune checkpoint protein that inhibits T cell activation in the tumor microenvironment [1] - B7-H3 is another immune checkpoint protein that regulates T cell responses and is often overexpressed in cancers [2] - Claudin 6 is a tight junction protein that regulates epithelial barrier integrity and is overexpressed in breast cancer, lung cancer, and endometrial cancer [2] AI-Driven Vaccine Design - The company will showcase two panels at the AACR 2025 Annual Meeting in collaboration with research partners, highlighting an AI-driven platform for designing cancer vaccines [2] - The use of the AI platform is expected to enhance the immunogenicity and efficacy of the designed vaccines [2] Clinical Trials - The company is accelerating its cancer vaccine research, with multiple therapeutic cancer vaccines at various stages, including clinical and preclinical phases [2] - The cancer vaccine seviprotimut-L is currently in the final research phase, being tested as an adjuvant therapy for melanoma patients post-surgery [2]

Financial Performance - For the fiscal year ending December 31, 2024, the company reported a loss attributable to shareholders of HKD 126.6 million, a decrease of HKD 143.9 million compared to a profit of HKD 17.3 million in 2023[7]. - The profit attributable to shareholders for 2023 was HKD 17.25 million, a significant decrease from HKD 131.96 million in 2022[95]. - Total revenue for the year ended December 31, 2023, was HKD 5,322.7 million, a slight increase from HKD 5,275.6 million in 2022[95]. - The fair value of the vineyard investment portfolio recorded a post-tax impairment of HKD 44 million in 2023, negatively impacting profits compared to the previous year[68]. - The group maintained a net debt to total equity ratio of approximately 58.36% as of December 31, 2024[97]. Research and Development - The company's investment in research and development increased from HKD 145.9 million in 2023 to HKD 254.1 million in 2024, representing an annual increase of HKD 102.8 million[11]. - The therapeutic cancer vaccine seviprotimut-L is currently in the final research phase, undergoing trials as an adjuvant therapy for melanoma patients post-surgery[10]. - Halneuron®, a non-opioid pain relief drug based on tetrodotoxin, is currently undergoing a Phase II clinical trial for chemotherapy-induced neuropathic pain[29]. - The company is expanding its therapeutic cancer vaccine portfolio, with promising laboratory results for vaccines targeting KRAS and PD-L1 presented at the AACR annual meeting[39]. - Jiangsu Life Science Technology is actively exploring the development of an AI-driven cancer vaccine discovery platform in collaboration with Crystal Technology, aiming to enhance the discovery and development process of new cancer vaccines[40]. Strategic Initiatives - The company is actively exploring innovative fields, including the use of artificial intelligence to accelerate the discovery and development of new cancer vaccines[12]. - The merger of WEX Pharmaceuticals with Virios Therapeutics to form Dogwood Therapeutics aims to expedite the development of Halneuron® for treating chemotherapy-induced neuropathic pain[9]. - The company plans to launch new formulations and implement innovative marketing strategies to capture the growing demand for health products post-COVID-19[15]. - The company has made strategic investments in liquid biopsy testing projects to provide non-invasive and cost-effective cancer detection solutions[13]. - The company is focused on developing unique products to meet consumer health needs, particularly in areas such as sleep, joint pain, immunity, and energy[62]. Environmental and Sustainability Efforts - The company is committed to sustainable development, as evidenced by the establishment of a Sustainability Committee[115]. - The company has acquired government grazing leases and rights to over 350,000 hectares of farmland in Australia for regenerative agriculture and carbon sequestration purposes, equivalent to more than three times the area of Hong Kong[133]. - Vitaquest has transitioned to using 100% renewable energy in 2024, reflecting the company's commitment to sustainable practices in health product manufacturing[134]. - The company is focused on identifying and addressing challenges and opportunities related to climate change, aiming to mitigate climate-related impacts and adapt to new environments[134]. - The company is committed to improving its environmental performance and has established policies and procedures to manage its environmental footprint[134]. Corporate Governance and Leadership - The company has a strong board of directors with members holding significant positions in various listed companies, enhancing corporate governance and strategic oversight[111][113][114][115]. - The company is focused on expanding its market presence and enhancing its product offerings through strategic appointments and experienced leadership[109][110]. - The leadership team has a strong educational background, with many members holding advanced degrees in relevant fields, contributing to informed decision-making[109][110][115]. - The company is committed to maintaining high standards of corporate governance and compliance through its experienced board members[116][121]. - The board includes independent directors with extensive backgrounds in finance, governance, and international relations, ensuring diverse perspectives in decision-making[113][115]. Market and Operational Strategies - Australian Agribusiness is implementing cost-cutting measures and adjusting product mix to alleviate the impact of material price fluctuations and high market inventory[18]. - The company is focused on enhancing operational efficiency, expanding sales, and improving productivity to promote internal growth[92]. - The company is implementing strategic operational measures to improve financial performance amid challenges such as high inflation and rising energy costs[86]. - The company has appointed a new independent non-executive director, Mr. Lo, who has extensive experience in finance and corporate governance[116]. - The company has a diverse executive team with members holding advanced degrees in business administration and law, enhancing its strategic capabilities[118][120]. Shareholder Information - As of December 31, 2024, the group’s major shareholder, Li Ka-shing, holds approximately 2,838,009,715 shares, representing 29.52% of total shares[146]. - Major shareholders include Gold Rainbow (BVI) Limited and its affiliates, holding approximately 4,355,634,570 shares, representing 45.31% of total shares[150]. - The company’s public float is approximately 24.99552%, which is below the minimum requirement of 25% as per listing rules[179]. - The board does not recommend the distribution of a final dividend for the fiscal year ending December 31, 2024[138]. - The total annual caps for continuing connected transactions I are set at HKD 100,000,000 for 2024, HKD 110,000,000 for 2025, and HKD 130,000,000 for 2026[164].

Company Overview - Changjiang Life Science Technology Group Limited is listed on the Hong Kong Stock Exchange and is a member of the CK Hutchison Group, focusing on the research, manufacturing, commercialization, promotion, sales, and investment in health, pharmaceuticals, diagnostics, and agriculture-related projects and assets [2]. Stock Performance - As of April 14, the Hang Seng Index rose by 2.4%, closing at 21,417.4 points. Changjiang Life Science Technology's stock closed at HKD 0.71 per share, up 16.39%, with a trading volume of 50.66 million shares and a turnover of HKD 33.68 million, showing a volatility of 16.39% [1]. - Over the past month, Changjiang Life Science Technology has seen a cumulative increase of 10.91%, and a year-to-date increase of 48.78%, outperforming the Hang Seng Index's increase of 4.26% [1]. Financial Performance - For the fiscal year ending December 31, 2024, Changjiang Life Science Technology reported total revenue of CNY 5.114 billion, a year-on-year increase of 3.76%. However, the net profit attributable to shareholders was a loss of CNY 117 million, a significant decrease of 833.65% compared to the previous year [1]. - The company's gross profit margin stands at 30.65%, with a debt-to-asset ratio of 67.45% [1]. Industry Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 11.13 times, with a median of 4.85 times. In comparison, Changjiang Life Science Technology has a P/E ratio of -46.33 times, ranking 85th in the industry [1]. - Other companies in the industry have the following P/E ratios: Qianjing Pharmaceutical (0.64), Kingsray Biotechnology (0.98), Baixin International (1.49), Dongrui Pharmaceutical (2.78), and Charoen Pokphand International (4.28) [1].

李嘉诚、李泽钜旗下长江生命科技(00775.HK)今日复牌一度大涨超40%，现缩小涨幅至30%以内。 ...

Group 1 - The company, Changjiang Life Science Technology, has announced promising early results from preclinical laboratory tests of a novel cancer vaccine targeting TROP2, a cell surface glycoprotein overexpressed in various cancers such as breast, lung, pancreatic, and colorectal cancers [1] - TROP2 plays a critical role in cell proliferation, metastasis, and invasion, making it a potential therapeutic target in oncology due to its high expression in cancer cells and minimal presence in normal tissues [1] - The TROP2 cancer vaccine candidate utilizes innovative circular RNA (circRNA) and fusion protein constructs, demonstrating significant tumor growth inhibition in preclinical studies involving over 170 mice, with complete tumor growth suppression observed in all breast cancer studies [1] Group 2 - The incidence of breast cancer, particularly triple-negative breast cancer (TNBC), is rising sharply in Asia, affecting many young women, with higher rates and severity compared to Western countries [2] - The company believes that the TROP2 cancer vaccine shows unprecedented anti-cancer efficacy based on mouse studies and aims to advance it to clinical research stages to provide new treatment options for patients [2] - The company has filed patent applications for the circRNA and fusion protein TROP2 cancer vaccine with the Hong Kong Intellectual Property Department and a provisional patent application with the U.S. Patent and Trademark Office [2] Group 3 - The company has applied to the Stock Exchange for the resumption of trading of its shares starting from 9:00 AM on April 11, 2025 [3]

李嘉诚、李泽钜旗下长江生命科技公布，周四（10日）上午9时正起短暂停止买卖，暂未悉因。 ...

智通财经APP获悉，长江生命科技(00775)绩后跌超6%，截至发稿，跌6.67%，报0.56港元，成交546.21 万港元。 港股异动 | 长江生命科技(00775)绩后跌超6% 年度 股东应占亏损1.27亿港元 同比盈转亏 公告称，业绩于2023年至2024年期间由盈转亏，主要归因于两大因素：公司决意加速科研，投资于科研 的支出由2023年1.46亿港元，上升至2024年2.54亿港元，按年增加1.08亿港元；以及葡萄园投资组合(除 具出售协议之物业外)的公平值取得税后贬值，按年减少4040万港元。 消息面上，3月18日，长江生命科技发布截至2024年12月31日止年度业绩，该集团期内取得收入55.23亿 港元，同比增加3.76%；公司股东应占亏损1.27亿港元，去年同期则公司股东应占溢利1725万港元；每 股基本亏损1.32港仙。 ...